234 related articles for article (PubMed ID: 7810496)
1. "Rescue" thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction.
White HD; Cross DB; Williams BF; Norris RM; Woo KS; Hamer AW; Elliott JM; Ormiston JA
Am J Cardiol; 1995 Jan; 75(2):172-4. PubMed ID: 7810496
[No Abstract] [Full Text] [Related]
2. Early patency in acute myocardial infarction.
Belenkie I
Can J Cardiol; 1993 Mar; 9(2):149-51. PubMed ID: 8490781
[No Abstract] [Full Text] [Related]
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
4. What you should know about thrombolytic therapy for acute MI.
Aragon D; Martin M
Am J Nurs; 1993 Sep; 93(9):24-31; quiz 33. PubMed ID: 8213959
[No Abstract] [Full Text] [Related]
5. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
6. Which thrombolytic agent should one choose?
Topol EJ
Prog Cardiovasc Dis; 1991; 34(3):165-78. PubMed ID: 1947122
[No Abstract] [Full Text] [Related]
7. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
[TBL] [Abstract][Full Text] [Related]
8. GISSI-2 and the heparin controversy.
White HD
Lancet; 1990 Aug; 336(8710):297-8. PubMed ID: 1973983
[No Abstract] [Full Text] [Related]
9. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
[TBL] [Abstract][Full Text] [Related]
10. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
GUSTO investigators
N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
[TBL] [Abstract][Full Text] [Related]
12. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
Bates ER
Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
[TBL] [Abstract][Full Text] [Related]
13. Thrombolytic therapy of myocardial infarction--it's time for science, not marketing: the perspective of a practicing cardiologist.
Vogel JH
Clin Cardiol; 1991 Jul; 14(7):548. PubMed ID: 1810292
[No Abstract] [Full Text] [Related]
14. The GUSTO trial: is the open-artery hypothesis proven?
Stringer KA; Lindenfeld J
Ann Pharmacother; 1994 Jan; 28(1):97-8. PubMed ID: 8123971
[No Abstract] [Full Text] [Related]
15. Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator.
Kimball BP; Bui S; Ling A; Dafopoulos N
Am Heart J; 1992 Jan; 123(1):7-14. PubMed ID: 1729852
[TBL] [Abstract][Full Text] [Related]
16. Future directions in thrombolysis for myocardial infarction: what are the unanswered questions?
Lefkovits J; Topol EJ
Coron Artery Dis; 1994 Apr; 5(4):306-16. PubMed ID: 8044342
[No Abstract] [Full Text] [Related]
17. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
Smith BJ
J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis in acute myocardial infarction.
Holmberg SR
Br J Hosp Med; 1992 Apr 15-May 5; 47(8):572-6, 578-80. PubMed ID: 1591557
[TBL] [Abstract][Full Text] [Related]
19. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
20. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy.
Mahaffey KW; Granger CB; Collins R; O'Connor CM; Ohman EM; Bleich SD; Col JJ; Califf RM
Am J Cardiol; 1996 Mar; 77(8):551-6. PubMed ID: 8610601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
